Search

Your search keyword '"WEWER ALBRECHTSEN, NICOLAI J."' showing total 616 results
Start Over Author "WEWER ALBRECHTSEN, NICOLAI J."
616 results on '"WEWER ALBRECHTSEN, NICOLAI J."'

3. Proteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children

Author

Nygaard, Ulrikka, Nielsen, Annelaura Bach, Dungu, Kia Hee Schultz, Drici, Lylia, Holm, Mette, Ottenheijm, Maud Eline, Nielsen, Allan Bybeck, Glenthøj, Jonathan Peter, Schmidt, Lisbeth Samsø, Cortes, Dina, Jørgensen, Inger Merete, Mogensen, Trine Hyrup, Schmiegelow, Kjeld, Mann, Matthias, Vissing, Nadja Hawwa, and Wewer Albrechtsen, Nicolai J.

Published
2024
Full Text
View/download PDF

6. The impact of short-term eucaloric low- and high-carbohydrate diets on liver triacylglycerol content in males with overweight and obesity: a randomized crossover study

Author

London, Amalie, Richter, Michael M, Sjøberg, Kim Anker, Wewer Albrechtsen, Nicolai J, Považan, Michal, Drici, Lylia, Schaufuss, Amanda, Madsen, Lise, Øyen, Jannike, Madsbad, Sten, Holst, Jens Juul, van Hall, Gerrit, Siebner, Hartwig Roman, Richter, Erik A, Kiens, Bente, Lundsgaard, Annemarie, and Bojsen-Møller, Kirstine Nyvold

Published
2024
Full Text
View/download PDF

7. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms

Author

Richter, Michael M., Kemp, Ida M., Heebøll, Sara, Winther-Sørensen, Marie, Kjeldsen, Sasha A.S., Jensen, Nicole J., Nybing, Janus D., Linden, Frederik H., Høgh-Schmidt, Erik, Boesen, Mikael P., Madsbad, Sten, Schiødt, Frank Vinholt, Nørgaard, Kirsten, Schmidt, Signe, Gluud, Lise Lotte, Haugaard, Steen B., Holst, Jens J., Nielsen, Søren, Rungby, Jørgen, and Wewer Albrechtsen, Nicolai J.

Published
2024
Full Text
View/download PDF

9. 100 years of glucagon and 100 more

Author

Wewer Albrechtsen, Nicolai J., Holst, Jens J., Cherrington, Alan D., Finan, Brian, Gluud, Lise Lotte, Dean, E. Danielle, Campbell, Jonathan E., Bloom, Stephen R., Tan, Tricia M.-M., Knop, Filip K., and Müller, Timo D.

Published
2023
Full Text
View/download PDF

10. Effects of 3 months of 10-h per-day time-restricted eating and 3 months of follow-up on bodyweight and cardiometabolic health in Danish individuals at high risk of type 2 diabetes: the RESET single-centre, parallel, superiority, open-label, randomised controlled trial

Author

Quist, Jonas Salling, Pedersen, Hanne Enghoff, Jensen, Marie Møller, Clemmensen, Kim Katrine Bjerring, Bjerre, Natasja, Ekblond, Trine Spragge, Uldal, Sarah, Størling, Joachim, Wewer Albrechtsen, Nicolai J, Holst, Jens Juul, Torekov, Signe Sørensen, Nyeland, Martin Erik, Vistisen, Dorte, Jørgensen, Marit Eika, Panda, Satchidananda, Brock, Christina, Finlayson, Graham, Blond, Martin Bæk, and Færch, Kristine

Published
2024
Full Text
View/download PDF

12. Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

Author

Kjeldsen, Sasha A.S., Gluud, Lise L., Werge, Mikkel P., Pedersen, Julie S., Bendtsen, Flemming, Alexiadou, Kleopatra, Tan, Tricia, Torekov, Signe S., Iepsen, Eva W., Jensen, Nicole J., Richter, Michael M., Goetze, Jens P., Rungby, Jørgen, Hartmann, Bolette, Holst, Jens J., Holst, Birgitte, Holt, Joachim, Gustafsson, Finn, Madsbad, Sten, Svane, Maria S., Bojsen-Møller, Kirstine N., and Wewer Albrechtsen, Nicolai J.

Published
2023
Full Text
View/download PDF

13. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight

Author

Svane, Maria S., Johannesen, Helle H., Hansen, Adam E., Martinussen, Christoffer, Bojsen-Møller, Kirstine N., Hansen, Martin Lundsgaard, Deacon, Carolyn F., Keller, Sune H., Klausen, Thomas L., Loft, Annika, Kjaer, Andreas, Löfgren, Johan, Madsbad, Sten, Holst, Jens J., and Wewer Albrechtsen, Nicolai J.

Published
2022
Full Text
View/download PDF

16. Glucagon, Metabolic Dysfunction-Associated Steatotic Liver Disease and Amino Acids in Humans and Animals without Diabetes Mellitus—An Evidence Map.

Author

Maruszczak, Katharina, Koren, Pia, Radzikowski, Konrad, Pixner, Thomas, Suppli, Malte Palm, Wewer Albrechtsen, Nicolai J., Weghuber, Daniel, and Torbahn, Gabriel

Subjects
EVIDENCE gaps, GLUCOSE tolerance tests, PANCREATIC beta cells, GLUCOSE clamp technique, CHILDHOOD obesity
Abstract

Introduction: Health systems are confronted with not only the growing worldwide childhood obesity epidemic but also associated comorbidities. These subsequently cause variations in distinct metabolic pathways, leading to metabolic dysfunction-associated steatotic liver disease (MASLD). The aim of this evidence map is to systematically evaluate the evidence and to identify research gaps on glucagon-induced amino acid (AA) turnover and its metabolic interaction with MASLD. Methodology: A systematic literature search was conducted up to April 2023 in three electronic databases. Studies were required to include at least two of the main research areas, glucagon, AA metabolism and MASLD. Two independent reviewers screened titles and abstracts according to prespecified eligibility criteria, as well as full-text articles. Results are summarized in tables stratified by human and animal studies and study population age. Results: Thirty-four references were ultimately included. The publication years dated back to 1965 showed a great increase from 2012 to 2023. In total, there were 19 animal studies and 15 human studies. Among the human studies, except for two studies in adolescents, all the studies were conducted in adults. In human studies, the methods used to evaluate metabolic changes differed among hyperinsulinemic-euglycemic clamp and oral glucose tolerance tests. Thirteen studies focused on the metabolic effects of MASLD, while only two studies explored the interaction between MASLD, glucagon and AA metabolism in humans. The other 19 studies focused on metabolomics, beta cell function or just one topic of a research area and not on interactions between one another. Conclusion: Research on the interaction between MASLD, glucagon and AA metabolism in humans is sparse and complete lacking in pediatrics. Furthermore, longitudinal studies with a focus on hyperglucagonemia independent of diabetes but related to MASLD present an unambiguous research gap. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Impairments of insulin and glucagon sensitivity in Chinese women with gestational diabetes mellitus.

Author

Zhang, Dan, Zhu, Jianan, Wewer Albrechtsen, Nicolai J., Rayner, Christopher K., Saffery, Richard, Zhang, Hua, Chen, Chang, and Wu, Tongzhi

Subjects
PATHOLOGICAL physiology, GLUCOSE tolerance tests, FATTY liver, BLOOD sugar, CHINESE people, INSULIN sensitivity, GESTATIONAL diabetes, INSULIN
Abstract

Aim: To evaluate insulin and glucagon sensitivity in Han Chinese women with and without gestational diabetes mellitus (GDM). Methods: In total, 81 women with GDM and 81 age‐matched healthy controls were evaluated with a 75 g oral glucose tolerance test (OGTT) at gestational weeks 24‐28. Plasma glucose concentrations were measured at fasting and 1 h and 2 h post‐OGTT. Fasting plasma insulin, glucagon and amino acids were also measured. Insulin and glucagon sensitivity were assessed by the homeostatic model assessment of insulin resistance (HOMA‐IR) and glucagon‐alanine index, respectively. Results: As expected, plasma glucose concentrations were higher at fasting and 1 h and 2 h post‐OGTT in GDM participants (p <.001 each). Both the HOMA‐IR and the glucagon‐alanine index were higher in GDM participants. There was a weak positive correlation between HOMA‐IR and glucagon‐alanine index (r = 0.24, p =.0024). Combining the HOMA‐IR and the glucagon‐alanine index yielded better capacity (area under the curve = 0.878) than either alone (area under the curve = 0.828 for HOMA‐IR and 0.751 for glucagon‐alanine index, respectively) in differentiating GDM from healthy participants. While the majority of GDM participants (64%) exhibited both reduced insulin and glucagon sensitivity, a third of them presented either reduced insulin (20%) or glucagon (14%) sensitivity alone. HOMA‐IR and glucagon‐alanine index correlated differentially with fasting glucose, triglycerides, low‐density lipoprotein cholesterol, sum of amino acids and hepatic steatosis index. Conclusions: Impairments of both insulin and glucagon sensitivity occur frequently in Chinese women with GDM, which may, individually or together, drive metabolic derangements in GDM. These observations provide new insights into the pathophysiology of GDM and support the need to target insulin or glucagon resistance, or both, in the management of GDM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice

Author

Galsgaard, Katrine D., Elmelund, Emilie, Johansen, Christian D., Bomholt, Anna B., Kizilkaya, Hüsün S., Ceutz, Frederik, Hunt, Jenna E., Kissow, Hannelouise, Winther-Sørensen, Marie, Sørensen, Charlotte M., Kruse, Thomas, Lau, Jesper F., Rosenkilde, Mette M., Ørskov, Cathrine, Christoffersen, Christina, Holst, Jens J., and Wewer Albrechtsen, Nicolai J.

Published
2022
Full Text
View/download PDF

21. Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease

Author

Jensen, Anne Sofie H., Ytting, Henriette, Werge, Mikkel P., Rashu, Elias B., Hetland, Liv E., Thing, Mira, Nabilou, Puria, Burisch, Johan, Bojsen-Møller, Kirstine N., Junker, Anders E., Hobolth, Lise, Mortensen, Christian, Tofteng, Flemming, Bendtsen, Flemming, Møller, Søren, Vyberg, Mogens, Serizawa, Reza R., Gluud, Lise L., Wewer Albrechtsen, Nicolai J., Jensen, Anne Sofie H., Ytting, Henriette, Werge, Mikkel P., Rashu, Elias B., Hetland, Liv E., Thing, Mira, Nabilou, Puria, Burisch, Johan, Bojsen-Møller, Kirstine N., Junker, Anders E., Hobolth, Lise, Mortensen, Christian, Tofteng, Flemming, Bendtsen, Flemming, Møller, Søren, Vyberg, Mogens, Serizawa, Reza R., Gluud, Lise L., and Wewer Albrechtsen, Nicolai J.

Abstract

Autoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown.In this cross-sectional study, we investigated the glucose-regulatory disturbances in patients with autoimmune hepatitis (AIH, n ¼19), primary biliary cholangitis (PBC, n ¼ 15), and primary sclerosing cholangitis (PSC, n ¼ 6). Healthy individuals (n ¼ 24) andpatients with metabolic dysfunction-associated steatotic liver disease (MASLD, n ¼ 18) were included as controls. Blood sampleswere collected during a 120-min oral glucose tolerance test. We measured the concentrations of glucose, C-peptide, insulin, glu-cagon, and the two incretin hormones, glucose insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). We calculatedthe homeostasis model assessment of insulin resistance (HOMA-IR), whole body insulin resistance (Matsuda index), insulin clear-ance, and insulinogenic index. All patient groups had increased fasting plasma glucose and impaired glucose responses com-pared with healthy controls. Beta-cell secretion was increased in AIH, PBC, and MASLD but not in PSC. Patients with AIH andMASLD had hyperglucagonemia and hepatic, as well as peripheral, insulin resistance and decreased insulin clearance, resultingin hyperinsulinemia. Patients with autoimmune liver disease had an increased GIP response, and those with AIH or PBC had anincreased GLP-1 response. Our data demonstrate that the mechanism underlying glucose disturbances in patients with autoim-mune liver disease differs from that underlying MASLD, including compensatory incretin responses in patients with autoimmuneliver disease. Our results suggest that glucose disturbances are present at an early stage of the disease. NEW & NOTEWORTHY Patients with autoimmune liver disease but without overt diabetes display glucose disturbances early onin their disease course. We identified pathophysiological traits specific to these patients including altered incretin responses., Autoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown. In this cross-sectional study, we investigated the glucose-regulatory disturbances in patients with autoimmune hepatitis (AIH, n = 19), primary biliary cholangitis (PBC, n = 15), and primary sclerosing cholangitis (PSC, n = 6). Healthy individuals (n = 24) and patients with metabolic dysfunction-associated steatotic liver disease (MASLD, n = 18) were included as controls. Blood samples were collected during a 120-min oral glucose tolerance test. We measured the concentrations of glucose, C-peptide, insulin, glucagon, and the two incretin hormones, glucose insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). We calculated the homeostasis model assessment of insulin resistance (HOMA-IR), whole body insulin resistance (Matsuda index), insulin clearance, and insulinogenic index. All patient groups had increased fasting plasma glucose and impaired glucose responses compared with healthy controls. Beta-cell secretion was increased in AIH, PBC, and MASLD but not in PSC. Patients with AIH and MASLD had hyperglucagonemia and hepatic, as well as peripheral, insulin resistance and decreased insulin clearance, resulting in hyperinsulinemia. Patients with autoimmune liver disease had an increased GIP response, and those with AIH or PBC had an increased GLP-1 response. Our data demonstrate that the mechanism underlying glucose disturbances in patients with autoimmune liver disease differs from that underlying MASLD, including compensatory incretin responses in patients with autoimmune liver disease. Our results suggest that glucose disturbances are present at an early stage of the disease.NEW & NOTEWORTHY Patients with autoimmune liver disease but without overt diabetes display glucose disturbances early on in their disease course. We identified pathophysiological traits specific to these patients including altered incretin responses.

Published
2024

22. Effects of 3 months of 10-h per-day time-restricted eating and 3 months of follow-up on bodyweight and cardiometabolic health in Danish individuals at high risk of type 2 diabetes:the RESET single-centre, parallel, superiority, open-label, randomised controlled trial

Author

Quist, Jonas Salling, Pedersen, Hanne Enghoff, Jensen, Marie Møller, Clemmensen, Kim Katrine Bjerring, Bjerre, Natasja, Ekblond, Trine Spragge, Uldal, Sarah, Størling, Joachim, Wewer Albrechtsen, Nicolai J., Holst, Jens Juul, Torekov, Signe Sørensen, Nyeland, Martin Erik, Vistisen, Dorte, Jørgensen, Marit Eika, Panda, Satchidananda, Brock, Christina, Finlayson, Graham, Blond, Martin Bæk, Færch, Kristine, Quist, Jonas Salling, Pedersen, Hanne Enghoff, Jensen, Marie Møller, Clemmensen, Kim Katrine Bjerring, Bjerre, Natasja, Ekblond, Trine Spragge, Uldal, Sarah, Størling, Joachim, Wewer Albrechtsen, Nicolai J., Holst, Jens Juul, Torekov, Signe Sørensen, Nyeland, Martin Erik, Vistisen, Dorte, Jørgensen, Marit Eika, Panda, Satchidananda, Brock, Christina, Finlayson, Graham, Blond, Martin Bæk, and Færch, Kristine

Abstract

Background: Time-restricted eating (TRE) has been suggested to be a simple, feasible, and effective dietary strategy for individuals with overweight or obesity. We aimed to investigate the effects of 3 months of 10-h per-day TRE and 3 months of follow-up on bodyweight and cardiometabolic risk factors in individuals at high risk of type 2 diabetes. Methods: This was a single-centre, parallel, superiority, open-label randomised controlled clinical trial conducted at Steno Diabetes Center Copenhagen (Denmark). The inclusion criteria were age 30–70 years with either overweight (ie, BMI ≥25 kg/m2) and concomitant prediabetes (ie, glycated haemoglobin [HbA1c] 39–47 mmol/mol) or obesity (ie, BMI ≥30 kg/m2) with or without prediabetes and a habitual self-reported eating window (eating and drinking [except for water]) of 12 h per day or more every day and of 14 h per day or more at least 1 day per week. Individuals were randomly assigned 1:1 to 3 months of habitual living (hereafter referred to as the control group) or TRE, which was a self-selected 10-h per-day eating window placed between 0600 h and 2000 h. Randomisation was done in blocks varying in size and was open for participants and research staff, but outcome assessors were masked during statistical analyses. The randomisation list was generated by an external statistician. The primary outcome was change in bodyweight, assessed after 3 months (12 weeks) of the intervention and after 3 months (13 weeks) of follow-up. Adverse events were reported and registered at study visits or if participants contacted study staff to report events between visits. This trial is registered on ClinicalTrials.gov (NCT03854656). Findings: Between March 12, 2019, and March 2, 2022, 100 participants (66 [66%] were female and 34 [34%] were male; median age 59 years [IQR 52–65]) were enrolled and randomly assigned (50 to each group). Of those 100, 46 (92%) in the TRE group and 46 (92%) in the control grou

Published
2024

23. Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes

Author

Richter, Michael M., Thomsen, Mads N., Skytte, Mads J., Kjeldsen, Sasha A.S., Samkani, Amirsalar, Frystyk, Jan, Magkos, Faidon, Holst, Jens J., Madsbad, Sten, Krarup, Thure, Haugaard, Steen B., Wewer Albrechtsen, Nicolai J., Richter, Michael M., Thomsen, Mads N., Skytte, Mads J., Kjeldsen, Sasha A.S., Samkani, Amirsalar, Frystyk, Jan, Magkos, Faidon, Holst, Jens J., Madsbad, Sten, Krarup, Thure, Haugaard, Steen B., and Wewer Albrechtsen, Nicolai J.

Abstract

Context Fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are increased in type 2 diabetes and are potential regulators of metabolism. The effect of changes in caloric intake and macronutrient composition on their circulating levels in patients with type 2 diabetes are unknown. Objective To explore the effects of a carbohydrate-reduced high-protein diet with and without a clinically significant weight loss on circulating levels of FGF21 and GDF15 in patients with type 2 diabetes. Methods We measured circulating FGF21 and GDF15 in patients with type 2 diabetes who completed 2 previously published diet interventions. Study 1 randomized 28 subjects to an isocaloric diet in a 6 + 6-week crossover trial consisting of, in random order, a carbohydrate-reduced high-protein (CRHP) or a conventional diabetes (CD) diet. Study 2 randomized 72 subjects to a 6-week hypocaloric diet aiming at a ∼6% weight loss induced by either a CRHP or a CD diet. Fasting plasma FGF21 and GDF15 were measured before and after the interventions in a subset of samples (n = 24 in study 1, n = 66 in study 2). Results Plasma levels of FGF21 were reduced by 54% in the isocaloric study (P < .05) and 18% in the hypocaloric study (P < .05) in CRHP-treated individuals only. Circulating GDF15 levels increased by 18% (P < .05) following weight loss in combination with a CRHP diet but only in those treated with metformin. Conclusion The CRHP diet significantly reduced FGF21 in people with type 2 diabetes independent of weight loss, supporting the role of FGF21 as a “nutrient sensor.” Combining metformin treatment with carbohydrate restriction and weight loss may provide additional metabolic improvements due to the rise in circulating GDF15., Context: Fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are increased in type 2 diabetes and are potential regulators of metabolism. The effect of changes in caloric intake and macronutrient composition on their circulating levels in patients with type 2 diabetes are unknown. Objective: To explore the effects of a carbohydrate-reduced high-protein diet with and without a clinically significant weight loss on circulating levels of FGF21 and GDF15 in patients with type 2 diabetes. Methods: We measured circulating FGF21 and GDF15 in patients with type 2 diabetes who completed 2 previously published diet interventions. Study 1 randomized 28 subjects to an isocaloric diet in a 6 + 6-week crossover trial consisting of, in random order, a carbohydrate-reduced high-protein (CRHP) or a conventional diabetes (CD) diet. Study 2 randomized 72 subjects to a 6-week hypocaloric diet aiming at a ∼6% weight loss induced by either a CRHP or a CD diet. Fasting plasma FGF21 and GDF15 were measured before and after the interventions in a subset of samples (n = 24 in study 1, n = 66 in study 2). Results: Plasma levels of FGF21 were reduced by 54% in the isocaloric study (P < .05) and 18% in the hypocaloric study (P < .05) in CRHP-treated individuals only. Circulating GDF15 levels increased by 18% (P < .05) following weight loss in combination with a CRHP diet but only in those treated with metformin. Conclusion: The CRHP diet significantly reduced FGF21 in people with type 2 diabetes independent of weight loss, supporting the role of FGF21 as a “nutrient sensor.” Combining metformin treatment with carbohydrate restriction and weight loss may provide additional metabolic improvements due to the rise in circulating GDF15.

Published
2024

24. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

Author

Winther-Sørensen, Marie, Galsgaard, Katrine D., Santos, Alberto, Trammell, Samuel A.J., Sulek, Karolina, Kuhre, Rune E., Pedersen, Jens, Andersen, Daniel B., Hassing, Anna S., Dall, Morten, Treebak, Jonas T., Gillum, Matthew P., Torekov, Signe S., Windeløv, Johanne A., Hunt, Jenna E., Kjeldsen, Sasha A.S., Jepsen, Sara L., Vasilopoulou, Catherine G., Knop, Filip K., Ørskov, Cathrine, Werge, Mikkel P., Bisgaard, Hanne Cathrine, Eriksen, Peter Lykke, Vilstrup, Hendrik, Gluud, Lise Lotte, Holst, Jens J., and Wewer Albrechtsen, Nicolai J.

Published
2020
Full Text
View/download PDF

30. Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes

Author

Richter, Michael M, primary, Thomsen, Mads N, additional, Skytte, Mads J, additional, Kjeldsen, Sasha A S, additional, Samkani, Amirsalar, additional, Frystyk, Jan, additional, Magkos, Faidon, additional, Holst, Jens J, additional, Madsbad, Sten, additional, Krarup, Thure, additional, Haugaard, Steen B, additional, and Wewer Albrechtsen, Nicolai J, additional

Published
2024
Full Text
View/download PDF

36. Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine

Author

Modvig, Ida M., Andersen, Daniel B., Grunddal, Kaare V., Kuhre, Rune E., Martinussen, Christoffer, Christiansen, Charlotte B., Ørskov, Cathrine, Larraufie, Pierre, Kay, Richard G., Reimann, Frank, Gribble, Fiona M., Hartmann, Bolette, Bojsen-Møller, Kirstine N., Madsbad, Sten, Wewer Albrechtsen, Nicolai J., and Holst, Jens J.

Published
2020
Full Text
View/download PDF

42. Discovery of plasma proteins associated with ventricular fibrillation during first ST-elevation myocardial infarction via proteomics

Author

Stampe, Niels Kjær, primary, Ottenheijm, Maud Eline, additional, Drici, Lylia, additional, Wewer Albrechtsen, Nicolai J, additional, Nielsen, Annelaura Bach, additional, Christoffersen, Christina, additional, Warming, Peder Emil, additional, Engstrøm, Thomas, additional, Winkel, Bo Gregers, additional, Jabbari, Reza, additional, Tfelt-Hansen, Jacob, additional, and Glinge, Charlotte, additional

Published
2023
Full Text
View/download PDF

43. SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy

Author

Sampson Kjeldsen, Sasha Alexandra, primary, Lotte Gluud, Lise, additional, Werge, Mikkel, additional, Steen Pedersen, Julie, additional, Bendtsen, Flemming, additional, Alexiadou, Kleopatra, additional, Tan, Tricia, additional, Torekov, Signe S, additional, Iepsen, Eva W, additional, Jensen, Nicole J, additional, Richter, Michael, additional, Hartmann, Bolette, additional, Holst, Jens J, additional, Holst, Birgitte, additional, Holt, Joachim, additional, Madsbad, Sten, additional, Svane, Maria S, additional, Bojsen-Møller, Kirstine N, additional, and Wewer Albrechtsen, Nicolai J, additional

Published
2023
Full Text
View/download PDF

44. Neprilysin activity is increased in MASLD and normalizes after bariatric surgery or GLP-1 therapy

Author

Kjeldsen, Sasha A.S., primary, Gluud, Lise L., additional, Werge, Mikkel P., additional, Pedersen, Julie S., additional, Bendtsen, Flemming, additional, Alexiadou, Kleopatra, additional, Tan, Tricia, additional, Torekov, Signe S., additional, Iepsen, Eva W., additional, Jensen, Nicole J., additional, Richter, Michael M., additional, Goetze, Jens P., additional, Rungby, Jørgen, additional, Hartmann, Bolette, additional, Holst, Jens J., additional, Holst, Birgitte, additional, Holt, Joachim, additional, Gustafsson, Finn, additional, Madsbad, Sten, additional, Svane, Maria S., additional, Bojsen-Møller, Kirstine N., additional, and Wewer Albrechtsen, Nicolai J., additional

Published
2023
Full Text
View/download PDF

46. Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes

Author

Kjeldsen, Sasha A S, primary, Thomsen, Mads N, additional, Skytte, Mads J, additional, Samkani, Amirsalar, additional, Richter, Michael M, additional, Frystyk, Jan, additional, Magkos, Faidon, additional, Hansen, Elizaveta, additional, Thomsen, Henrik S, additional, Holst, Jens J, additional, Madsbad, Sten, additional, Haugaard, Steen B, additional, Krarup, Thure, additional, and Wewer Albrechtsen, Nicolai J, additional

Published
2023
Full Text
View/download PDF

50. No direct effect of SGLT2 activity on glucagon secretion

Author

Kuhre, Rune E., Ghiasi, Seyed M., Adriaenssens, Alice E., Wewer Albrechtsen, Nicolai J., Andersen, Daniel B., Aivazidis, Alexander, Chen, Lihua, Mandrup-Poulsen, Thomas, Ørskov, Cathrine, Gribble, Fiona M., Reimann, Frank, Wierup, Nils, Tyrberg, Björn, and Holst, Jens J.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results